Department of Neurology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Neuropsychiatr Dis Treat. 2009;5:505-15. doi: 10.2147/ndt.s5236. Epub 2009 Oct 12.
Vigabatrin (VGB) is an antiepileptic drug that was designed to inhibit GABA-transaminase, and increase levels of gamma-amino-butyric acid (GABA), a major inhibitory neurotransmitter in the brain. VGB has demonstrated efficacy as an adjunctive antiepileptic drug for refractory complex partial seizures (CPS) and for infantile spasms (IS). This review focuses on its use for complex partial seizures. Although VGB is well tolerated, there have been significant safety concerns about intramyelinic edema and visual field defects. VGB is associated with a risk of developing bilateral concentric visual field defects. Therefore, the use of VGB for complex partial seizures should be limited to those patients with seizures refractory to other treatments. Patients must have baseline and follow-up monitoring of visual fields, early assessment of its efficacy, and ongoing evaluation of the benefits and risks of VGB therapy.
氨己烯酸（VGB）是一种抗癫痫药物，旨在抑制 GABA 转氨酶，并增加γ-氨基丁酸（GABA）的水平，GABA 是大脑中的主要抑制性神经递质。VGB已被证明作为辅助抗癫痫药物对难治性复杂部分性发作（CPS）和婴儿痉挛（IS）有效。本综述重点介绍其在复杂部分性发作中的应用。尽管 VGB 耐受性良好，但人们对髓鞘内水肿和视野缺陷存在重大安全担忧。VGB 与发展为双侧同心视野缺陷相关。因此，VGB 用于复杂部分性发作的使用应限于对其他治疗方法耐药的患者。患者必须进行基线和随访视野监测，早期评估其疗效，并持续评估 VGB 治疗的益处和风险。
